The treatment of severe malaria.
In the SEAQUAMAT trial, parenteral artesunate was shown to be associated with a considerably lower mortality than quinine, and is now the recommended treatment for severe malaria in low-transmission areas and in the second and third trimesters of pregnancy. A trial is underway to establish its role...
Principais autores: | Dondorp, A, Day, N |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2007
|
Registros relacionados
-
The treatment of severe malaria
por: Dondorp, A
Publicado em: (2007) -
The management of patients with severe malaria.
por: Day, N, et al.
Publicado em: (2007) -
Cost-effectiveness of artesunate for the treatment of severe malaria.
por: Lubell, Y, et al.
Publicado em: (2009) -
UK recommendations for severe malaria are worrying.
por: White, N, et al.
Publicado em: (2007) -
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.
por: Dondorp, A, et al.
Publicado em: (2005)